Effects of gene polymorphism on efficacy and toxic effect of chemotherapy regimen containing oxaliplatin treatment in stage Ⅲ and Ⅳ colorectal cancer
- VernacularTitle:基因多态性对含奥沙利铂化疗方案治疗Ⅲ、Ⅳ期结直肠癌疗效及毒副作用的影响
- Author:
Liuxing TANG
1
;
Bo LYU
1
;
Wenting JIANG
1
;
Zheng XIANG
1
;
Zhu SHEN
1
;
Jie PAN
1
;
Cunjin SU
1
Author Information
1. Dept. of Pharmacy，the Second Affiliated Hospital of Soochow University，Jiangsu Suzhou 215004，China
- Publication Type:Journal Article
- Keywords:
oxaliplatin;
gene polymorphism;
colorectal cancer;
efficacy;
toxic effect;
correlation
- From:
China Pharmacy
2024;35(6):734-738
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the effects of GSTP1， XRCC1， ABCB1， MTHFR gene polymorphisms on efficacy and toxic effect of chemotherapy regimen containing oxaliplatin in patients with stage Ⅲ and Ⅳ colorectal cancer patients. METHODS Clinical data of 76 patients with stage Ⅲ and Ⅳ colorectal cancer who received chemotherapy regimen containing oxaliplatin （XELOX，FOLFOX） were collected from the Second Affiliated Hospital of Soochow University from September 2018 to March 2020. The correlation of genotypes with progression-free survival （PFS） and toxic effect was analyzed by using univariate and multivariate COX regression model. RESULTS Carriers of the ABCB1 3435T＞C locus C allele （TC/CC） had a significantly higher risk of progression compared to TT genotype patients [HR＝2.39， 95%CI （1.05，5.50）， P＝0.038]. The risk of progression in patients at stage Ⅳ was significantly higher than those at stage Ⅲ [HR＝8.11， 95%CI（3.39，19.40）， P＜0.001]. Chemotherapy regimen， Karnofsky performance status score and tumor site had no significant effect on disease progression （P＞0.05）. Mutations in gene loci were not correlated with adverse reactions （P＞0.05）. CONCLUSIONS Patients carrying ABCB1 TC/CC and receiving chemotherapy regimen containing oxaliplatin have a higher risk of disease progression， which may be associated with longer PFS in patients （TT genotype） with stage Ⅳ colorectal cancer receiving the chemotherapy， while GSTP1， XRCC1， and MTHFR gene polymorphisms have no significant impact.
